Although approximately 80% of patients with MG are not able to achieve CSR, clinical factors and pathologic factors, such as thymic tumor stage, have not been shown to significantly impact a patient's path to CSR. These data suggest that the presence of thymoma is much more influential than other disease factors typically considered prognostic.
Results from a study by Baggi and colleagues demonstrate that the likelihood of CSR is lower in patients with thymoma than in those with involuted thymus histologic findings or thymic hyperplasia.
Learn more about the treatment of patients with MG.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Raghav Govindarajan. Fast Five Quiz: Refractory Myasthenia Gravis - Medscape - Oct 13, 2021.
Comments